Natalizumab
- IVNatalizumabTysabri
Mechanism of Action
- Monoclonal antibody toward leucocyte adhesion molecules, resulting in slowed entry of T cells into the CNS.
Clinical Use
Indications
- Relapsing-remitting multiple sclerosis (MS).
- Contraindications
- Other immunomodulatory agents
- Immunocompromised patients
- Adverse Effects
- Progressive multifocal leukencephalopathy (PML)
- Headache
- Fatigue
- Arthralgia
- Increased risk of infection